Jinliang Peng

Dr. Jinliang Peng


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
LYLiuxin Yang
Liuxin Yang
YYYang Yang
Yang Yang
YCYang Chen
Yang Chen
YXYuhong Xu
Yuhong Xu
JPJinliang Peng
Jinliang Peng

12 January 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
AWAnqi Wang
Anqi Wang
YZYuan Zheng
Yuan Zheng
WZWanxin Zhu
Wanxin Zhu
LYLiuxin Yang
Liuxin Yang
YYYang Yang
Yang Yang
JPJinliang Peng
Jinliang Peng
Melittin (MEL) is a 26-amino acid polypeptide with a variety of pharmacological and toxicological effects, which include strong surface activity on cell lipid membranes, hemolytic activity, and potential anti-tumor properties. However, the clinical application of melittin is restricted due to its severe hemolytic activity. Different nanocarrier systems have been developed to achieve stable loading, side effects shielding, and tumor-targeted delivery, such as liposomes, cationic polymers, lipodisks, etc. In addition, MEL can be modified on nano drugs as a non-selective cytolytic peptide to enhance cellular uptake and endosomal/lysosomal escape. In this review, we discuss recent advances in MEL’s nano-delivery systems and MEL-modified nano drug carriers for cancer therapy.

18 November 2021 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
RYRan Ye
Ran Ye
YZYuan Zheng
Yuan Zheng
YCYang Chen
Yang Chen
XWXiaohui Wei
Xiaohui Wei
SSSanyuan Shi
Sanyuan Shi
JPJinliang Peng
Jinliang Peng

10 October 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PZPei-Jie Zhou
Pei-Jie Zhou
WXWei Xue
Wei Xue
JPJinliang Peng
Jinliang Peng
YWYanqing Wang
Yanqing Wang
LWLianzi Wei
Lianzi Wei
Wei-Qiang GaoWei-Qiang Gao
Wei-Qiang Gao
Prostate cancer (PCa) is one of the most frequent tumors and leading cause of cancer deaths among males worldwide. The majority of deaths are due to recurrence and subsequent development of the metastatic cancer. Although loss or dislocalization of polarity proteins has been implicated in embryogenesis deficiency and tumorigenesis, association of polarity protein expression levels with tumor metastasis remains unclear. Bioinformatics, qRT-PCR, western blot and immunohistochemical (IHC) analyses were used to examine expression of Par3, a key component of polarity-associated partitioning defective (PAR) complex, in primary and metastatic clinical PCa samples. Loss-of-function and gain-of-function studies in vitro and in vivo were performed to determine the functions of Par3 during metastasis of PCa. Co-immunoprecipitation (co-IP), western blot, immunofluorescence (IF), chromatin immunoprecipitation (ChIP) and qRT-PCR analyses were conducted to investigate the underlying mechanism for the function of Par3 on PCa metastasis. In this study, we found that elevated expression of Par3 is positively associated with PCa metastasis. Knockdown of Par3 inhibits PCa cell migration and invasion in vitro and tumor metastasis in vivo, whereas overexpression of Par3 yields the opposite results. Mechanistically, Par3 suppresses phosphorylation of LATS to inactivate the Hippo pathway and enhances nuclear translocation of YAP by sequestrating KIBRA from the KIBRA/Merlin/FRMD6 complex and forming a Par3/aPKC/KIBRA complex. Stable knockdown of Par3 leads to restoration of the KIBRA/Merlin/FRMD6 complex and activation of the Hippo pathway, and then results in an inhibition on YAP nuclear translocation. In addition, in conjunction with the TEA domain (TEAD) transcription factor family, intranuclear YAP promotes the transcription of several pro-metastatic genes such as the matrix metalloproteinase (MMP) family, Zeb1, Snail1 and Twist1. Moreover, knockdown of Par3 downregulates expression of these pro-metastatic genes. Our findings indicate that elevated expression of Par3 promotes PCa metastasis via KIBRA sequestration-mediated inactivation of the Hippo pathway to upregulate expression of pro-metastatic genes. Downregulation of Par3 expression may serve as a potential treatment approach for PCa metastasis by activating the Hippo pathway.

1 February 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SLSai Lu
Sai Lu
XBXiao Bao
Xiao Bao
WHWangxi Hai
Wangxi Hai
SSSanyuan Shi
Sanyuan Shi
YCYuetan Chen
Yuetan Chen
JPJinliang Peng
Jinliang Peng

30 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZYZhen Yang
Zhen Yang
YZYunlong Zan
Yunlong Zan
XZXiujuan Zheng
Xiujuan Zheng
WHWangxi Hai
Wangxi Hai
KCKewei Chen
Kewei Chen
JPJinliang Peng
Jinliang Peng
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been widely used in oncologic procedures such as tumor diagnosis and staging. However, false-positive rates have been high, unacceptable and mainly caused by inflammatory lesions. Misinterpretations take place especially when non-subcutaneous inflammations appear at the tumor site, for instance in the lung. The aim of the current study is to evaluate the use of dynamic PET imaging procedure to differentiate in situ and subcutaneous non-small cell lung carcinoma (NSCLC) from inflammation, and estimate the kinetics of inflammations in various locations. Dynamic FDG-PET was performed on 33 female mice inoculated with tumor and/or inflammation subcutaneously or inside the lung. Standardized Uptake Values (SUVs) from static imaging (SUVmax) as well as values of influx rate constant (Ki) of compartmental modeling from dynamic imaging were obtained. Static and kinetic data from different lesions (tumor and inflammations) or different locations (subcutaneous, in situ and spontaneous group) were compared. Values of SUVmax showed significant difference in subcutaneous tumor and inflammation (p<0.01), and in inflammations from different locations (p<0.005). However, SUVmax showed no statistical difference between in situ tumor and inflammation (p = 1.0) and among tumors from different locations (subcutaneous and in situ, p = 0.91). Values of Ki calculated from compartmental modeling showed significant difference between tumor and inflammation both subcutaneously (p<0.005) and orthotopically (p<0.01). Ki showed also location specific values for inflammations (subcutaneous, in situ and spontaneous, p<0.015). However, Ki of tumors from different locations (subcutaneous and in situ) showed no significant difference (p = 0.46). In contrast to static PET based SUVmax, both subcutaneous and in situ inflammations and malignancies can be differentiated via dynamic FDG-PET based Ki. Moreover, Values of influx rate constant Ki from compartmental modeling can offer an assessment for inflammations at different locations of the body, which also implies further validation is necessary before the replacement of in situ inflammation with its subcutaneous counterpart in animal experiments.